Oral Semaglutide and SNAC: A Physician’s Read on the First Peptide Pill for Weight

Andres Zuleta, MD · A physician's read

In medical school I learned a simple rule: peptides are injected, because the gut digests them. Oral semaglutide is the first GLP-1 peptide to break that rule at scale, and how it does so has practical consequences for every patient who takes it.

The mechanism

Semaglutide is coformulated with sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC). Buckley and colleagues (Sci Transl Med 2018, PMID 30429357) showed in clinical and canine studies that absorption occurs in the stomach, confined to the area next to the tablet surface, and requires SNAC. SNAC buffers the local pH, protecting against pepsin degradation, and transiently enhances transcellular absorption, without evidence of tight junction opening.

Why dosing instructions matter

Absolute bioavailability is under 1% (FDA labels). Food, larger volumes of water and other tablets in the stomach reduce exposure, hence fasting administration with up to 4 oz of water and a 30 minute wait. The Wegovy tablet is titrated from 1.5 mg every 30 days to a 25 mg maintenance dose.

The trials

• PIONEER 1 (Diabetes Care 2019, PMID 31186300): 703 adults with type 2 diabetes, 26 weeks; HbA1c -0.6, -0.9 and -1.1 points at 3, 7 and 14 mg (treatment policy).
• OASIS 1 (Lancet 2023, PMID 37385278): 667 adults without diabetes, 50 mg daily, 68 weeks: -15.1% vs -2.4%; GI adverse events 80% vs 46%.
• OASIS 4 (NEJM 2025, PMID 40934115): 307 adults without diabetes, 25 mg daily, 64 weeks: -13.6% vs -2.2%; GI adverse events 74.0% vs 42.2%.
• SOUL (NEJM 2025, PMID 40162642): 9,650 adults with type 2 diabetes and ASCVD and/or CKD, up to 14 mg: MACE 12.0% vs 13.8% (HR 0.86, 95% CI 0.77 to 0.96); confirmatory kidney outcome not significant.

Regulatory status

Rybelsus was approved for type 2 diabetes in September 2019. The Wegovy tablet (oral semaglutide 25 mg) was approved by the FDA on December 22, 2025, for chronic weight management and MACE risk reduction in adults with established cardiovascular disease and obesity or overweight.

What remains open

• Real-world adherence to the fasting routine, and how much exposure varies outside trials.
• Head-to-head comparisons with injectable semaglutide 2.4 mg at matched durations.
• All phase 3 trials were sponsor funded.
• Compounded or online "oral semaglutide" drops, sprays or tablets lack the SNAC formulation data and are not the studied product.

My read

The pharmacology is elegant and humbling: a formulation that delivers under 1% of the dose still matches much of the weekly injection's effect, because semaglutide is potent and long lived. For patients, the choice between pill and shot is mostly about routine, tolerance and preference, and the conversation should start there.

The patient-friendly version, with every source: https://www.thrivemed.us/thrivecityblog/peptide-pill-oral-semaglutide-snac

Educational only, not medical advice. Andres Zuleta, MD.